Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067129 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT03067129 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 129 participants.
The verdict
NCT03067129, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in children ages 3 to \< 12 years.
Interventions
- DRUG Glecaprevir/Pibrentasvir Adult Formulation
- DRUG Glecaprevir + Pibrentasvir Pediatric Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2022-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03067129
The ClinicalTrials.gov registry entry for NCT03067129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glecaprevir/Pibrentasvir Adult Formulation is the first listed.
NCT03067129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03067129 about?
NCT03067129 is a clinical study titled "A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection". The objectives of this study are to assess the pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir adult formulation in adolescents ages 12 to 17 years and a pediatric formulation of glecaprevir and pibrentasvir in children ages 3 to \< 12 years.
What is the current status of trial NCT03067129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2017-03-20. Estimated completion is 2022-09-12.
What interventions are being tested in trial NCT03067129?
The interventions under investigation include: Glecaprevir/Pibrentasvir Adult Formulation (DRUG), Glecaprevir + Pibrentasvir Pediatric Formulation (DRUG).
Who is sponsoring clinical trial NCT03067129?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.